800-331-6634

Latest News

Gene Therapy Approved by the FDA

Mid Atlantic Retina is pleased that the FDA has approved gene therapy, voretigene (Luxturna), for very specific uncommon genetic retinal diseases, caused by mutations in the gene RPE65 which may cause a form of Leber Congenital Amaurosis or retinitis pigmentosa.  These disorders cause severe loss of vision starting at birth or in early childhood.  Not ... read more

2017 ADA Step Out Walk

Mid Atlantic Retina partnered with the American Diabetes Association for their Annual Step Out Walk on Saturday, November 4th in Philadelphia. This was our 7th year in partnership with the ADA raising awareness and funds to stop diabetes. It was a great day for a great cause!... read more

Read All